Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 5, Issue 3, Pages 455-464Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.5.3.455
Keywords
allogeneic hemopoietic stem cell transplantation; autologous hemopoietic stem cell transplantation; donor lymphocyte infusion; graft-versus-host disease; graft-versus-myeloma; myeloma
Categories
Ask authors/readers for more resources
Multiple myeloma is currently incurable using standard treatment regimens. While the introduction of high-dose chemotherapy with autologous stem cell rescue has been shown to increase overall survival when compared with chemotherapy alone, this strategy is palliative. Allogeneic stem cell transplantation provides the potential for long-term disease-free survival in a small proportion of patients, although its application has been limited by procedure-related mortality, reflecting the intensive myeloablative conditioning given. Recently, reduced intensity conditioning regimens have been developed in an attempt to reduce toxicity whilst preserving the allogeneic graft-versus-myeloma effect, therefore maintaining the potential for disease eradication. This review aims to examine the current position of allogeneic transplantation in the management of myeloma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available